Cubist Pharma Cvr (CBSTZ) 0.06 $CBSTZ
Diarrhea Therapeutic Pipeline Review H1 2015 Market Research Report - New at ReportsnReports.com
PRWeb - Sat Jan 31, 3:30AM CST
The report "Diarrhea - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for diarrhea. Diarrhea describes loose, watery stools that occur more repeatedly than usual. The most common cause of diarrhea is the stomach flu. Eating or drinking food or water that contains certain types of bacteria or parasites can also lead to diarrhea. Diarrhea and related complications can cause severe ill health. The most significant cause of severe ill health is loss of water and electrolytes. Signs and symptoms of diarrhea include dehydration, failure to thrive and malnutrition, abdominal pain, borborygmi and perianal erythema. Diarrheal disease may have a negative impact on both physical fitness and mental development. Complete Report is Available @ http://www.reportsnreports.com/reports/328713...-2015.html.
FURX: 104.77 (-1.41), CBSTZ: 0.06 (unch), PFE: 34.64 (-0.23), ASMB: 10.46 (+0.46), PRTK: 26.95 (+0.65), NVS: 102.20 (-0.17)
Product and Pipeline Analysis of the Antibacterial Drugs Market 2015
M2 - Sat Jan 31, 12:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/knzdss/a_product_and) has announced the addition of the "A Product and Pipeline Analysis of the Antibacterial Drugs Market " report to their offering. Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) market, with particular focus on the antibiotics currently under development. A list of currently available and marketed antibacterial drugs under the approved antibacterial drug classes has been provided. Product and pipeline assessment for recently approved antibacterial drugs, antibacterials under FDA review, as well as phase 3 antibacterial drug candidates have been provided. A detailed overview of the various regulatory approaches to foster innovation in the development of new antibiotics has been provided as well. Antibacterial Drugs Listed - Tedizolid Phosphate-Cubist Pharmaceuticals - Dalbavancin (Dalvance)-Durata Therapeutics - Ceftolozane Tazobactam-Cubist Pharmaceuticals - Oritavancin (Orbactiv)-The Medicines Company - Ceftazidime Avibactam (CAZ-AVI)-AstraZeneca - Cadazolid-Actelion Pharmaceuticals - Carbavance-Rempex Pharmaceuticals (The Medicines Company) - Delafloxacin-Melinta Therapeutics - Eravacycline-Tetraphase Pharmaceuticals - Plazomicin-Achaogen - Solithromycin-Cempra Pharmaceuticals - Surotomycin-Cubist Pharmaceuticals Key Topics Covered: 1. Executive Summary 2. Introduction 3. Classification Of Antibacterial Drugs By Mechanism Of Action 4. Antibacterial Drugs Market-Pipeline Analysis 5. Antibacterial Drugs Market-Major Clinical Milestones 6. Antibacterial Drugs Market-Product Dashboard Of Recently Approved And Late-Stage Pipeline Drug Candidates 7. Antibiotic Resistance-A Critical Unmet Need That Poses Challenges To Antibiotic R&D 8. Antibacterial Drugs Market-Timeline Of Key Events 9. Regulatory Approaches To Stimulate Antibiotics R&D 10. Antibacterial Drugs Market-Key Companies To Watch 11. Conclusions 12. Appendix Companies Mentioned - Achaogen - Actelion Pharmaceuticals - AstraZeneca - Cempra Pharmaceuticals - Cubist Pharmaceuticals - Durata Therapeutics - Melinta Therapeutics - Rempex Pharmaceuticals - Tetraphase Pharmaceuticals - The Medicines Company For more information visit http://www.researchandmarkets.com/research/kn...roduct_and
DRTX: 24.16 (+0.41), TTPH: 35.18 (-0.73), CBSTZ: 0.06 (unch), MDCO: 29.79 (+0.91)
$CTIX - Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon
KarinCA - at Seeking Alpha - Thu Jan 29, 3:13PM CST
JNJ: 99.62 (+1.18), CBSTZ: 0.06 (unch), ACT: 285.37 (+3.71), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), ABBV: 58.05 (+1.00), NVS: 102.20 (-0.17)
Dimension Therapeutics Appoints Successful Biopharma Leader Mary Thistle as Chief Business Officer
Business Wire - Wed Jan 28, 7:00AM CST
Dimension Therapeutics, Inc. ("Dimension" or the "Company"
, a rare disease company advancing novel treatments for diverse genetic disorders of the liver based upon an AAV gene therapy platform, today announced that Mary Thistle, former senior vice president, business development at Cubist Pharmaceuticals, has been appointed to the newly created position of chief business officer. Ms. Thistle will report directly to Dimension's CEO Annalisa Jenkins, MBBS, MRCP, and her appointment is effective February 2.
CBSTZ: 0.06 (unch)
Merck Announces CHMP Issues Positive Opinion for Investigational Antibiotic SIVEXTRO(R) (tedizolid phosphate)
Business Wire - Mon Jan 26, 7:30AM CST
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of the investigational antibiotic SIVEXTRO(R) (tedizolid phosphate) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Merck acquired SIVEXTRO as a part of its purchase, through a subsidiary, of Cubist Pharmaceuticals, Inc.
CBSTZ: 0.06 (unch), MRK: 58.81 (-0.07)
Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist's 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020
Business Wire - Thu Jan 22, 2:29PM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced that, in connection with the completion of the acquisition of Cubist by Merck, Cubist has commenced a tender offer (the "Convertible Notes Tender Offer" to repurchase, at the option of each holder, any and all of its outstanding 2.50% Convertible Senior Notes due 2017 (the "2017 Convertible Notes" , 1.125% Convertible Senior Notes due 2018 (the "2018 Convertible Notes" and 1.875% Convertible Senior Notes due 2020 (the "2020 Convertible Notes" and together with the 2017 Convertible Notes and 2018 Convertible Notes, the "Convertible Notes" . Earlier in the day on January 21, 2015, Merck completed the tender offer for all of the outstanding shares of common stock of Cubist, consummated the merger of Cubist into Mavec Corporation, Inc., a wholly owned subsidiary of Merck, and terminated trading of Cubist's common stock on the Nasdaq Global Select Market, each of which constituted a Fundamental Change (as defined in each of the indentures governing the Convertible Notes (the "Indentures" ) triggering Cubist's obligation to commence the Convertible Notes Tender Offer.
CBSTZ: 0.06 (unch), MRK: 58.81 (-0.07)
Merck concludes tender offer to acquire Cubist at USD102.00 per share
M2 - Thu Jan 22, 5:34AM CST
Healthcare company Merck (NYSE:MRK) said on Wednesday that it has acquired all of the outstanding shares of common stock of Cubist Pharmaceuticals (NasdaqGS:CBST) at a purchase price of USD102.00 per share in a tender offer.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
Merck Completes Tender Offer to Acquire Cubist
Business Wire - Wed Jan 21, 7:00AM CST
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the tender offer for all of the outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) at a purchase price of $102.00 per share. As of the tender offer expiration yesterday, 58,039,667 shares of common stock of Cubist were validly tendered and not properly withdrawn from the tender offer, representing approximately 75.7 percent of the outstanding common stock of Cubist on a fully diluted basis. All of such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for all such shares.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
Dana Holding Set to Join the S&P MidCap 400
PR Newswire - Tue Jan 20, 4:45PM CST
Dana Holding Corp. (NYSE: DAN) will replace Cubist Pharmaceuticals Inc. (NASD: CBST) in the S&P MidCap 400 after the close of trading on Thursday, January 22. S&P 100 & 500 constituent Merck & Co. Inc. (NYSE: MRK) is acquiring Cubist Pharmaceuticals in a transaction expected to be completed soon, pending final conditions.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07), DAN: 22.96 (-0.04), MHFI: 102.19 (unch)
Cubist Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market
Business Wire - Tue Jan 13, 7:00AM CST
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will voluntarily withdraw the contingent value rights (CVRs) it issued under a Contingent Value Rights Agreement dated October 24, 2013 (CVR Agreement) from listing on the NASDAQ Global Select Market on February 2, 2015, contemporaneously with their redemption. The CVRs are currently listed under the symbol CBSTZ.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14)
Vericel Corporation Names Three New Board Members
Marketwired - Wed Jan 07, 7:45AM CST
Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the appointment of three new members to the company's board of directors: Steven C. Gilman, Ph.D., executive vice president and chief scientific officer of Cubist Pharmaceuticals; Kevin F. McLaughlin, senior vice president and chief financial officer of Acceleron Pharma; and Paul Wotton, Ph.D., president and chief executive officer of Ocata Therapeutics.
CBSTZ: 0.06 (unch), VCEL: 3.71 (-0.01), XLRN: 38.02 (+0.07)
Biotech Stocks Technical Data -- Gilead Sciences, ImmunoGen, Exelixis, Cubist Pharma, and Vanda Pharma
PR Newswire - Tue Dec 30, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), ImmunoGen Inc. (NASDAQ: IMGN), Exelixis Inc. (NASDAQ: EXEL), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, December 29, 2014, ended flat as the Dow Jones Industrial Average finished at 18,038.23, down 0.09% and the NASDAQ Composite ended at previous day's closing of 4,806.91. The S&P 500 finished the session 0.09% higher at 2,090.57. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 803.07, up 0.26%, with the index advancing 7.88% in the previous three months. Register for your complimentary reports on these five stocks at:
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), GILD: 101.90 (+1.10), VNDA: 12.37 (unch), IMGN: 7.19 (unch), EXEL: 2.48 (+0.20)
Merck begins tender offer to acquire Cubist
M2 - Mon Dec 22, 6:43AM CST
Healthcare company Merck (NYSE:MRK) said on Friday that its subsidiary has started a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals (NasdaqGS:CBST).
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
Merck Begins Tender Offer to Acquire Cubist
Business Wire - Fri Dec 19, 7:00AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ:CBST). On Dec. 8, 2014, Merck announced its intent to acquire Cubist.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company
PR Newswire - Mon Dec 15, 6:07PM CST
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cubist Pharmaceuticals, Inc. ("Cubist Pharmaceuticals" or the "Company" (Nasdaq-CBST- News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Merck & Co.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc. - CBST
PR Newswire - Fri Dec 12, 7:30PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cubist Pharmaceuticals, Inc. ("Cubist" or the "Company" (Nasdaq: CBST) for potential breaches of fiduciary duties in connection with the sale of the Company to Merck & Co., Inc. ("Merck" (NYSE: MRK) for approximately $9.5 billion in an all-cash transaction. The Company's stockholders will receive $102 for each share of Cubist common stock they own.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Fri Dec 12, 4:07PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cubist Pharmaceuticals, Inc. ("Cubist" or the "Company" (Nasdaq: CBST) relating to the proposed buyout of the Company by Merck & Co., Inc. ("Merck" .
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co.
Business Wire - Fri Dec 12, 9:19AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Cubist Pharmaceuticals, Inc. (NasdaqGS: CBST) ("Cubist" in connection with the sale of the Company to Merck & Co.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Thu Dec 11, 1:22PM CST
Rigrodsky & Long, P.A.:
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
Diarrhea Therapeutic Pipeline Review H1 2015 Market Research Report - New at ReportsnReports.com
PRWeb - Sat Jan 31, 3:30AM CST
The report "Diarrhea - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for diarrhea. Diarrhea describes loose, watery stools that occur more repeatedly than usual. The most common cause of diarrhea is the stomach flu. Eating or drinking food or water that contains certain types of bacteria or parasites can also lead to diarrhea. Diarrhea and related complications can cause severe ill health. The most significant cause of severe ill health is loss of water and electrolytes. Signs and symptoms of diarrhea include dehydration, failure to thrive and malnutrition, abdominal pain, borborygmi and perianal erythema. Diarrheal disease may have a negative impact on both physical fitness and mental development. Complete Report is Available @ http://www.reportsnreports.com/reports/328713...-2015.html.
FURX: 104.77 (-1.41), CBSTZ: 0.06 (unch), PFE: 34.64 (-0.23), ASMB: 10.46 (+0.46), PRTK: 26.95 (+0.65), NVS: 102.20 (-0.17)
Product and Pipeline Analysis of the Antibacterial Drugs Market 2015
M2 - Sat Jan 31, 12:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/knzdss/a_product_and) has announced the addition of the "A Product and Pipeline Analysis of the Antibacterial Drugs Market " report to their offering. Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) market, with particular focus on the antibiotics currently under development. A list of currently available and marketed antibacterial drugs under the approved antibacterial drug classes has been provided. Product and pipeline assessment for recently approved antibacterial drugs, antibacterials under FDA review, as well as phase 3 antibacterial drug candidates have been provided. A detailed overview of the various regulatory approaches to foster innovation in the development of new antibiotics has been provided as well. Antibacterial Drugs Listed - Tedizolid Phosphate-Cubist Pharmaceuticals - Dalbavancin (Dalvance)-Durata Therapeutics - Ceftolozane Tazobactam-Cubist Pharmaceuticals - Oritavancin (Orbactiv)-The Medicines Company - Ceftazidime Avibactam (CAZ-AVI)-AstraZeneca - Cadazolid-Actelion Pharmaceuticals - Carbavance-Rempex Pharmaceuticals (The Medicines Company) - Delafloxacin-Melinta Therapeutics - Eravacycline-Tetraphase Pharmaceuticals - Plazomicin-Achaogen - Solithromycin-Cempra Pharmaceuticals - Surotomycin-Cubist Pharmaceuticals Key Topics Covered: 1. Executive Summary 2. Introduction 3. Classification Of Antibacterial Drugs By Mechanism Of Action 4. Antibacterial Drugs Market-Pipeline Analysis 5. Antibacterial Drugs Market-Major Clinical Milestones 6. Antibacterial Drugs Market-Product Dashboard Of Recently Approved And Late-Stage Pipeline Drug Candidates 7. Antibiotic Resistance-A Critical Unmet Need That Poses Challenges To Antibiotic R&D 8. Antibacterial Drugs Market-Timeline Of Key Events 9. Regulatory Approaches To Stimulate Antibiotics R&D 10. Antibacterial Drugs Market-Key Companies To Watch 11. Conclusions 12. Appendix Companies Mentioned - Achaogen - Actelion Pharmaceuticals - AstraZeneca - Cempra Pharmaceuticals - Cubist Pharmaceuticals - Durata Therapeutics - Melinta Therapeutics - Rempex Pharmaceuticals - Tetraphase Pharmaceuticals - The Medicines Company For more information visit http://www.researchandmarkets.com/research/kn...roduct_and
DRTX: 24.16 (+0.41), TTPH: 35.18 (-0.73), CBSTZ: 0.06 (unch), MDCO: 29.79 (+0.91)
$CTIX - Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon
KarinCA - at Seeking Alpha - Thu Jan 29, 3:13PM CST
JNJ: 99.62 (+1.18), CBSTZ: 0.06 (unch), ACT: 285.37 (+3.71), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), ABBV: 58.05 (+1.00), NVS: 102.20 (-0.17)
Dimension Therapeutics Appoints Successful Biopharma Leader Mary Thistle as Chief Business Officer
Business Wire - Wed Jan 28, 7:00AM CST
Dimension Therapeutics, Inc. ("Dimension" or the "Company"
, a rare disease company advancing novel treatments for diverse genetic disorders of the liver based upon an AAV gene therapy platform, today announced that Mary Thistle, former senior vice president, business development at Cubist Pharmaceuticals, has been appointed to the newly created position of chief business officer. Ms. Thistle will report directly to Dimension's CEO Annalisa Jenkins, MBBS, MRCP, and her appointment is effective February 2. CBSTZ: 0.06 (unch)
Merck Announces CHMP Issues Positive Opinion for Investigational Antibiotic SIVEXTRO(R) (tedizolid phosphate)
Business Wire - Mon Jan 26, 7:30AM CST
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of the investigational antibiotic SIVEXTRO(R) (tedizolid phosphate) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Merck acquired SIVEXTRO as a part of its purchase, through a subsidiary, of Cubist Pharmaceuticals, Inc.
CBSTZ: 0.06 (unch), MRK: 58.81 (-0.07)
Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist's 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020
Business Wire - Thu Jan 22, 2:29PM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced that, in connection with the completion of the acquisition of Cubist by Merck, Cubist has commenced a tender offer (the "Convertible Notes Tender Offer"
to repurchase, at the option of each holder, any and all of its outstanding 2.50% Convertible Senior Notes due 2017 (the "2017 Convertible Notes" , 1.125% Convertible Senior Notes due 2018 (the "2018 Convertible Notes" and 1.875% Convertible Senior Notes due 2020 (the "2020 Convertible Notes" and together with the 2017 Convertible Notes and 2018 Convertible Notes, the "Convertible Notes" . Earlier in the day on January 21, 2015, Merck completed the tender offer for all of the outstanding shares of common stock of Cubist, consummated the merger of Cubist into Mavec Corporation, Inc., a wholly owned subsidiary of Merck, and terminated trading of Cubist's common stock on the Nasdaq Global Select Market, each of which constituted a Fundamental Change (as defined in each of the indentures governing the Convertible Notes (the "Indentures" ) triggering Cubist's obligation to commence the Convertible Notes Tender Offer. CBSTZ: 0.06 (unch), MRK: 58.81 (-0.07)
Merck concludes tender offer to acquire Cubist at USD102.00 per share
M2 - Thu Jan 22, 5:34AM CST
Healthcare company Merck (NYSE:MRK) said on Wednesday that it has acquired all of the outstanding shares of common stock of Cubist Pharmaceuticals (NasdaqGS:CBST) at a purchase price of USD102.00 per share in a tender offer.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
Merck Completes Tender Offer to Acquire Cubist
Business Wire - Wed Jan 21, 7:00AM CST
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the tender offer for all of the outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) at a purchase price of $102.00 per share. As of the tender offer expiration yesterday, 58,039,667 shares of common stock of Cubist were validly tendered and not properly withdrawn from the tender offer, representing approximately 75.7 percent of the outstanding common stock of Cubist on a fully diluted basis. All of such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for all such shares.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
Dana Holding Set to Join the S&P MidCap 400
PR Newswire - Tue Jan 20, 4:45PM CST
Dana Holding Corp. (NYSE: DAN) will replace Cubist Pharmaceuticals Inc. (NASD: CBST) in the S&P MidCap 400 after the close of trading on Thursday, January 22. S&P 100 & 500 constituent Merck & Co. Inc. (NYSE: MRK) is acquiring Cubist Pharmaceuticals in a transaction expected to be completed soon, pending final conditions.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07), DAN: 22.96 (-0.04), MHFI: 102.19 (unch)
Cubist Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market
Business Wire - Tue Jan 13, 7:00AM CST
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will voluntarily withdraw the contingent value rights (CVRs) it issued under a Contingent Value Rights Agreement dated October 24, 2013 (CVR Agreement) from listing on the NASDAQ Global Select Market on February 2, 2015, contemporaneously with their redemption. The CVRs are currently listed under the symbol CBSTZ.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14)
Vericel Corporation Names Three New Board Members
Marketwired - Wed Jan 07, 7:45AM CST
Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the appointment of three new members to the company's board of directors: Steven C. Gilman, Ph.D., executive vice president and chief scientific officer of Cubist Pharmaceuticals; Kevin F. McLaughlin, senior vice president and chief financial officer of Acceleron Pharma; and Paul Wotton, Ph.D., president and chief executive officer of Ocata Therapeutics.
CBSTZ: 0.06 (unch), VCEL: 3.71 (-0.01), XLRN: 38.02 (+0.07)
Biotech Stocks Technical Data -- Gilead Sciences, ImmunoGen, Exelixis, Cubist Pharma, and Vanda Pharma
PR Newswire - Tue Dec 30, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), ImmunoGen Inc. (NASDAQ: IMGN), Exelixis Inc. (NASDAQ: EXEL), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, December 29, 2014, ended flat as the Dow Jones Industrial Average finished at 18,038.23, down 0.09% and the NASDAQ Composite ended at previous day's closing of 4,806.91. The S&P 500 finished the session 0.09% higher at 2,090.57. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 803.07, up 0.26%, with the index advancing 7.88% in the previous three months. Register for your complimentary reports on these five stocks at:
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), GILD: 101.90 (+1.10), VNDA: 12.37 (unch), IMGN: 7.19 (unch), EXEL: 2.48 (+0.20)
Merck begins tender offer to acquire Cubist
M2 - Mon Dec 22, 6:43AM CST
Healthcare company Merck (NYSE:MRK) said on Friday that its subsidiary has started a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals (NasdaqGS:CBST).
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
Merck Begins Tender Offer to Acquire Cubist
Business Wire - Fri Dec 19, 7:00AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ:CBST). On Dec. 8, 2014, Merck announced its intent to acquire Cubist.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company
PR Newswire - Mon Dec 15, 6:07PM CST
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cubist Pharmaceuticals, Inc. ("Cubist Pharmaceuticals" or the "Company"
(Nasdaq-CBST- News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Merck & Co. CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc. - CBST
PR Newswire - Fri Dec 12, 7:30PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cubist Pharmaceuticals, Inc. ("Cubist" or the "Company"
(Nasdaq: CBST) for potential breaches of fiduciary duties in connection with the sale of the Company to Merck & Co., Inc. ("Merck" (NYSE: MRK) for approximately $9.5 billion in an all-cash transaction. The Company's stockholders will receive $102 for each share of Cubist common stock they own. CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Fri Dec 12, 4:07PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cubist Pharmaceuticals, Inc. ("Cubist" or the "Company"
(Nasdaq: CBST) relating to the proposed buyout of the Company by Merck & Co., Inc. ("Merck" . CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co.
Business Wire - Fri Dec 12, 9:19AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Cubist Pharmaceuticals, Inc. (NasdaqGS: CBST) ("Cubist"
in connection with the sale of the Company to Merck & Co. CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Thu Dec 11, 1:22PM CST
Rigrodsky & Long, P.A.:
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
